|Systematic (IUPAC) name|
|Licence data||EMA: , US FDA:|
|Pregnancy cat.||B3 (AU) C (US)|
|Legal status||Prescription Only (S4) (AU) ℞-only (US)|
|Routes||oral- extended release, long-acting, once-monthly IM injection|
|Half-life||23 hours (oral)|
|Mol. mass||426.484 g/mol|
|(what is this?)|
Paliperidone (trade name Invega), also known as 9-hydroxyrisperidone, is a dopamine antagonist of the atypical antipsychotic class of medications. It is developed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once-daily dosing. Paliperidone palmitate (trade name Invega Sustenna, named Xeplion in Europe) is a long-acting injectable formulation of paliperidone palmitoyl ester indicated for once-monthly injection after an initial titration period. Paliperidone is used to treat mania and at lower doses as maintenance for bipolar disorder. It is also used for schizophrenia and schizoaffective disorder.
Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not identical, pathways.
Paliperidone has antagonist effect at α1 and α2 adrenergic receptors and at H1 histamine receptors. It does not bind to muscarinic acetylcholine receptors. In addition it binds with dopamine and serotonin receptors.
Paliperidone (as Invega) was approved by the FDA for the treatment of schizophrenia in 2006. It is marketed for the treatment of schizophrenia and schizoaffective disorder. Paliperidone was approved by the FDA for the treatment of schizoaffective disorder in 2009. It may also be used off-label for other conditions. Recently, the long-acting injectable form of paliperidone, marketed as INVEGA Sustenna in U.S. and Xeplion in Europe, was approved by the FDA on July 31, 2009. It was approved in Europe in 2011 for schizophrenia. In Europe the monthly (every 28 days) injection comes in 50 mg, 75 mg, 100 mg, and 150 mg of paliperidone without the 25 mg injection that is available in the U.S. A dose of 75 mg for a month in an injection is the equivalent of 6 mg per day of paliperidone oral. 6 mg of paliperidone oral (Invega) is equivalent to 2 to 3 mg of risperidone.
Adverse Effect Incidences
- Very Common (>10% incidence)
- Somnolence (causes less sedation than most atypical antipsychotics)
- Hyperprolactinaemia (seems to cause comparable prolactin elevation to its parent drug, risperidone)
- Common (1-10% incidence)
- Extrapyramidal side effects (EPSE; e.g. dystonia, akathisia, muscle rigidity, parkinsonism. It appears to produce similar EPSE to risperidone, asenapine and ziprasidone and more EPSE than olanzapine, clozapine, aripiprazole, quetiapine, amisulpride and sertindole)
- Orthostatic hypotension
- Weight gain (tends to produce a moderate degree of weight gain, possibly related to its potent blockade of the 5-HT2C receptor)
- QT interval prolongation (tends to produce less QT interval prolongation than most other atypical antipsychotics and approximately as much QT interval as aripiprazole and lurasidone)
- Rare/Uncommon (<1% incidence)
- Neuroleptic malignant syndrome which is a potentially life-threatening condition characterised by:
- - Hyperthermia
- - Muscle rigidity
- - Autonomic dysregulation
- - Mental status changes (e.g. confusion, agitation, etc.)
- - Dysphagia
- - Tremor
- - Dyspnoea
- - Elevated creatine kinase
- Tardive dyskinesia, an often irreversible neurologic condition characterised by, frequently distressing, movement disorders.
- Agranulocytosis, a potentially fatal drop in white blood cell count. More common in patients on clozapine than in those on paliperidone.
- Atrial fibrilation
- Diabetes mellitus
- Diabetic ketoacidosis
- Urinary retention
- "The DrugBank database".
- "Prescribing Reference: New Product Releases - INVEGA". Retrieved 2008-05-25.
- Truven Health Analytics, Inc. DrugPoint® System (Internet) [cited 2013 Sep 30]. Greenwood Village, CO: Thomsen Healthcare; 2013.
- INVEGA® PRODUCT INFORMATION [Internet]. Janssen Pharmaceuticals; 2013 [cited 2013 Sep 30]. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-01421-1
- Joint Formulary Committee. British National Formulary (BNF) 65. Pharmaceutical Pr; 2013.
- paliperidone (Rx) - Invega, Invega Sustenna [Internet]. Medscape Reference. [cited 2013 Sep 30]. Available from: http://reference.medscape.com/drug/invega-sustenna-paliperidone-342992#4
- Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet [Internet]. [cited 2013 Sep 30]; Available from: http://www.sciencedirect.com/science/article/pii/S0140673613607333
- Tonkonogy J, Sholevar DP. Neuroleptic Malignant Syndrome. 2012 Jun 17 [cited 2013 Sep 30]; Available from: http://emedicine.medscape.com/article/288482-clinical
- Brasic JR. Tardive Dyskinesia. 2012 Jun 17 [cited 2013 Sep 30]; Available from: http://emedicine.medscape.com/article/1151826-overview#aw2aab6b7
- INVEGA Web site
- INVEGA Sustenna (paliperidone palmitate Extended Release Injectable Suspension) Web site